X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DISHMAN PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DISHMAN PHARMA GLENMARK PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 17.4 25.1 69.3% View Chart
P/BV x 3.0 3.3 90.9% View Chart
Dividend Yield % 0.3 0.7 52.0%  

Financials

 GLENMARK PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
GLENMARK PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs930374 248.4%   
Low Rs517129 401.4%   
Sales per share (Unadj.) Rs322.6197.8 163.1%  
Earnings per share (Unadj.) Rs28.521.2 134.3%  
Cash flow per share (Unadj.) Rs39.234.7 112.9%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.30.8 34.8%  
Book value per share (Unadj.) Rs183.0179.9 101.7%  
Shares outstanding (eoy) m282.1780.69 349.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.3 176.3%   
Avg P/E ratio x25.411.9 214.1%  
P/CF ratio (eoy) x18.57.2 254.8%  
Price / Book Value ratio x4.01.4 282.7%  
Dividend payout %7.09.4 74.4%   
Avg Mkt Cap Rs m204,20620,306 1,005.7%   
No. of employees `00013.70.8 1,654.5%   
Total wages/salary Rs m18,7185,355 349.6%   
Avg. sales/employee Rs Th6,636.819,252.7 34.5%   
Avg. wages/employee Rs Th1,364.76,459.5 21.1%   
Avg. net profit/employee Rs Th586.12,064.1 28.4%   
INCOME DATA
Net Sales Rs m91,03115,961 570.3%  
Other income Rs m914265 344.4%   
Total revenues Rs m91,94516,226 566.7%   
Gross profit Rs m16,1544,103 393.7%  
Depreciation Rs m3,0191,091 276.8%   
Interest Rs m2,856944 302.4%   
Profit before tax Rs m11,1932,334 479.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155624 505.9%   
Profit after tax Rs m8,0391,711 469.8%  
Gross profit margin %17.725.7 69.0%  
Effective tax rate %28.226.7 105.5%   
Net profit margin %8.810.7 82.4%  
BALANCE SHEET DATA
Current assets Rs m69,88711,018 634.3%   
Current liabilities Rs m32,8799,517 345.5%   
Net working cap to sales %40.79.4 432.3%  
Current ratio x2.11.2 183.6%  
Inventory Days Days81110 73.7%  
Debtors Days Days9335 268.4%  
Net fixed assets Rs m28,89216,304 177.2%   
Share capital Rs m282161 174.8%   
"Free" reserves Rs m51,35312,907 397.9%   
Net worth Rs m51,63514,516 355.7%   
Long term debt Rs m41,4184,189 988.6%   
Total assets Rs m125,95429,805 422.6%  
Interest coverage x4.93.5 141.7%   
Debt to equity ratio x0.80.3 277.9%  
Sales to assets ratio x0.70.5 135.0%   
Return on assets %8.68.9 97.1%  
Return on equity %15.611.8 132.1%  
Return on capital %15.117.5 86.1%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m36,3174,952 733.5%   
Fx outflow Rs m9,720697 1,394.9%   
Net fx Rs m26,5984,255 625.1%   
CASH FLOW
From Operations Rs m16,4812,786 591.5%  
From Investments Rs m-10,133-1,529 662.8%  
From Financial Activity Rs m-4,685-941 497.8%  
Net Cashflow Rs m1,770316 559.4%  

Share Holding

Indian Promoters % 48.3 61.4 78.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 3.7 186.5%  
FIIs % 34.4 12.7 270.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 22.1 47.5%  
Shareholders   56,727 46,261 122.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   MERCK LTD  STERLING BIOTECH  TORRENT PHARMA  SUVEN LIFE  CIPLA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 146 Points Lower; IT and Power Stocks Drag(Closing)

Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.Sectoral indices ended on a mixed note with realty stocks.

Related Views on News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 19, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS